normally be considered to show a poor response to anti-hypertensive treatment. Furthermore, we expect the a 1 -blocker doxazosin to demonstrate a dose-dependent effect in obese patients with hypertension.
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In this cross-sectional study, we surveyed a population of 101 hypertensive patients in Japan to determine the efficacy of the blood pressure lowering effect of a 1 -blockers in relation to their body mass index (BMI). We found that doxazosin was frequently administered to obese hypertensive patients; many patients treated with doxazosin were taking concomitant medication. We also demonstrated that the higher the dose of doxazosin, the lower the ambulatory blood pressure measured in the out-patient clinic. Doxazosin showed a more favourable blood pressure lowering effect in patients with a higher BMI. These results suggest that anti-hypertensive drugs are useful when used in obese patients receiving multiple concomitant medications. These patients would
Introduction
Many epidemiological surveys have revealed that obesity is frequently complicated by hypertension and that the majority of patients with hypertension are obese. Epidemiological studies have also demonstrated that obesity is closely related to the onset of hypertension in most cases. It has been suggested that the mechanism underlying this association is the activation of the sympathetic nervous system caused by insulin resistance or hyperleptinaemia, which is often associated with obesity. Alpha 1 -blockers exert their anti-hypertensive effect by inhibiting the α 1 -receptors of the sympathetic nervous system, causing relaxation of the vascular smooth muscles and lowering vascular resistance. α 1 -Blockers are attracting attention because they improve the insulin resistance and abnormal lipid metabolism often seen in obese people, suggesting that they may be appropriate for patients with obesity-associated hypertension. The JSH guidelines recommend use of α 1 -blockers for treating obese patients with hypertension complicated by abnormal glucose metabolism, insulin resistance, or abnormal lipid metabolism. 2 In this cross-sectional study, the current status of treatment with α 1 -blockers was assessed in a selected Japanese population. The relationship between body mass index (BMI; weight [kg]/height [m] 2 ) and antihypertensive effectiveness of the α 1 -blocker doxazosin was evaluated. In addition, three case reports are presented. These show data from 24-h ambulatory home blood pressure monitoring where doxazosin was admin-istered in combination with other agents or as a monotherapy to obese hypertensive patients with diabetes mellitus.
Patients and methods

STUDY POPULATION
Patients with hypertension who were being treated with α 1 -blockers were recruited to the study at the cardiovascular department of 11 medical institutions in the Kagawa and Ehime prefectures, Japan (see Acknowledgements). Ethical approval was not necessary for this type of study, but all attending physicians sought verbal informed consent from the patients.
STUDY METHODS
A questionnaire was distributed to all participating physicians that asked for information about variables that would contribute to an analysis of the relationship between BMI and anti-hypertensive effects. Data on the patient's treatment with α 1 -blockers, dosing patterns, blood pressure, BMI, concomitant drug use and comorbidities were sought ( Table 1) . Ambulatory blood pressure and pulse rate were measured using standard methods.
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Results
PATIENTS
A total of 101 patients with hypertension who were being treated with α 1 -blockers were enrolled in the study and their treatment history evaluated. The mean age of the patients was 65 ± 12 years, and there were 69 men (mean age, 65 ± 11 years) and 32 women (mean age, 64 ± 13 years).
DOSAGE PATTERNS
The α 1 -blockers used were doxazosin (92%), bunazosin (7%), and prazosin (1%). Doxazosin was the most frequently used α 1 -blocker so we focused our analysis on doxazosin and the subpopulation of patients treated with doxazosin became the study population (n = 93). The most common dose of doxazosin was 4 mg/day, followed by 8 mg/day, 2 mg/day and 1 mg/day. The 4 mg and 8 mg daily doses constituted about 75% of the total doses of doxazosin administered.
The highest mean dose of doxazosin was found in the 30 -39 years age group and the lowest mean dose in the 80 -89 years age group. The results showed a tendency towards a pattern of the younger the patient, the higher the dose of doxazosin, but the results were not statistically significant.
A single dose of doxazosin was the most frequently used administration schedule in nearly half of the patients. None of the patients received doxazosin in the middle of the day, and more than half received the drug in the evening or at bedtime (evening, bedtime, morning and evening, morning and bedtime).
The dose of doxazosin was associated with a dose-dependent reduction in systolic blood pressure, but the result was not significant.
The highest dose of doxazosin was administered to patients with hypertension and diabetes mellitus.
COMORBIDITIES
Forty per cent of patients had no comorbidities, 27% had hyperlipidaemia, about 12% had diabetes mellitus, and about 5% of patients had both disorders in addition to hypertension.
CONCOMITANT ANTI-HYPERTENSIVE MEDICATIONS
We found that calcium channel blockers (75%) were the drug class used most frequently in combination with doxazosin, followed by β-blockers (37%), ACE inhibitors (35%), ARBs (25%) and diuretics (12%).
With regard to the relationship between the number of concomitant drugs used and ambulatory blood pressure, the study found that both systolic and diastolic blood pressure continued to be lowered as the number of concomitant drugs used was increased. The data showed that the dose of doxazosin also increased (but not significantly) with an increase in the number of concomitant drugs used.
RELATIONSHIP BETWEEN BMI AND DOSAGE PATTERNS
The dose of doxazosin (1 mg/day, 2 mg/day, 4 mg/day or 8 mg/day) that was used was not dependent upon the BMI. However, when the number of concomitant drugs that were used was analysed, the study found that more non-obese patients (BMI ≤ 25) received monotherapy, and that the number of concomitant drugs used increased with increasing BMI (but not significantly; Fig. 1 ). In other words, as the patients became more S Toyonaga, T Nakatsu, C Suezawa et al.
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obese, the number of concomitant drugs that they used increased.
RELATIONSHIP BETWEEN BMI AND THERAPEUTIC EFFICACY
The relationship between BMI and the antihypertensive effect of doxazosin therapy was studied in the 93 patients. The mean age of this study population was 64 ± 12 years and the mean dose of doxazosin was 4.2 ± 2.1 mg/day. The BMI and ambulatory systolic blood pressure were investigated in 71 patients treated with doxazosin (including concomitant drugs), to study the relationship between BMI and anti-hypertensive effect of treatment. Weight or height data were unavailable for the remaining 22 patients, so they could not be included in this analysis. A negative correlation (not significant) was observed between the two variables, with the doxazosin-containing anti-hypertensive regimen being more effective in patients with a higher BMI (Fig. 2 ).
CASE REPORTS
Case 1
This was a 76-year-old obese (BMI = 27) man with hypertension and diabetes mellitus. This patient had high blood pressure in the morning, which was inadequately controlled by a calcium channel blocker and an ACE inhibitor. Doxazosin (2 mg/day), administered before bedtime reduced the morning blood pressure (Fig. 3 ).
Case 2
This was a 35-year-old obese (BMI = 32.9; grade 2 obesity) woman with hypertension and diabetes mellitus. This patient was taking a calcium channel blocker in combination with an ARB. Doxazosin (2 mg/day), administered in the morning, was added to the existing regimen to attain 
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the lower blood pressure target recommended by various guidelines for patients with diabetes mellitus 1 (S Toyonaga, personal communication, 2003). The combination therapy resulted in good blood pressure control in the morning and evening (Fig. 4 ).
Case 3
This was a 69-year-old obese (BMI = 26.7) woman with hypertension and diabetes mellitus. This patient's blood pressure was 160 -180 mmHg systolic and 100 -120 mmHg diastolic in the morning, and 170 -190 mmHg systolic and 90 -110 mmHg diastolic in the evening. Monotherapy with doxazosin 4 mg/day, administered in the morning, produced a good blood pressure reduction in both the morning and evening (Fig. 5 ).
Discussion
This study surveyed the characteristics of treatment with doxazosin in 93 patients with hypertension, and analysed the relationship between the BMI and the effectiveness of anti-hypertensive therapy. More non-obese patients were treated with doxazosin monotherapy when compared with obese patients. However, in view of the higher BMI in patients receiving multiple therapeutic agents and the low frequency of doxazosin monotherapy, doxazosin was more likely to be used in obese patients. These results confirmed those of our previous survey that showed that BMI is significantly higher in patients being treated with α 1 -blockers compared with those not receiving α 1 -blockers, and that doxazosin is more likely to be used as combination therapy than monotherapy (S Toyonaga, personal communication, 2003). A multicentre study of around 150 000 men and women in Japan aged 30 -79 years reported that the incidence of hypertension, hypercholesterolaemia, or hyperglycaemia increases with an increase in BMI. These findings suggest that an increase of only 3 units in BMI above the standard 22 will double the rate of these complications. 3 The highest dose of doxazosin was administered to patients with hypertension and diabetes mellitus. This was thought to be A negative correlation was observed between BMI and the blood pressure lowering effect of doxazosin, suggesting that doxazosin is more effective in reducing blood pressure in patients with a higher BMI. The mechanism responsible for increasing blood pressure in obesity has been suggested to be an activation of the sympathetic nervous system caused by insulin resistance 4 -7 or high blood levels of leptin. 8 -10 A previous study of the relationship between obesity and leptin showed a positive correlation between BMI and plasma concentrations of leptin in both men and women, suggesting that increased levels of leptin may be involved in the increase in blood pressure often seen in obese people (S Toyonaga, personal communication, 2003) . In a study where urine was collected over 24 h from 80 patients with hypertension, excretion of urinary norepinephrine was reported to be significantly increased in obese patients compared with patients of normal weight. This suggested that activation of the sympathetic nervous system is involved in the increase in blood pressure seen in obese patients with hypertension. 11 α 1 -Blockers, which improve insulin resistance by suppressing activation of the sympathetic nervous system, are therefore attracting attention for their efficacy in obese patients with hypertension. 12, 13 Our study results support this favourable profile for doxazosin. It is likely that the efficacy of doxazosin in obese patients with hypertension will be more clearly elucidated in larger studies in the future.
Data from the case reports suggest that α 1 -blockers are suitable for treating hypertension associated with obesity, and even a single administration in the morning can reduce the morning blood pressure. Measuring blood pressure at home was also found to be an excellent method of helping to control the morning blood pressure. 14 The adverse event profile of α 1 -blockers is characterized by orthostatic hypotension, S Toyonaga, T Nakatsu, C Suezawa et al.
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but the incidence of this has been relatively reduced by using long-acting α 1 -blockers like doxazosin. In a study investigating the relationship between the change in orthostatic blood pressure and the use of doxazosin, excessive reduction in blood pressure attributable to the orthostatic load was only observed in 2 out of 54 patients, and blood pressure remained unchanged upon standing in most patients (S Toyonaga, personal communication, 2003). To prevent adverse reactions, such as orthostatic hypotension, physicians are recommended to gradually increase the dose from a low initial dose. In patients with a history of orthostatic hypotension, the use of doxazosin should be carefully monitored.
In Japan, adopting Westernized food habits has increased the incidence of obesity, although it is characteristically 'milder' than that seen in US and European populations: most obese Japanese people have a BMI between 25 and 27, with few having a BMI > 28. The incidence of obesity-related disease however, is not low in Japanese people, who may be more sensitive to the adverse effects of obesity. Hence, as treating obesity and associated hypertension becomes more necessary, the clinical significance and roles of α 1 -blockers in this condition become increasingly important.
Our results indicate that combination therapy with anti-hypertensive drugs is useful in obese patients who are generally 
